ArticleBMC nephrology2025
Alterations in serum exosomal miR-1207-5p levels reflect severity and progression risk in type 2 diabetic kidney disease.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Urinary Extracellular Vesicle-Derived miRNAs as Regulators and Biomarkers in Diabetic Kidney Disease.International journal of molecular sciences · 2026Review
- Exosome-mediated cell-cell communication: a new perspective on the mechanisms and therapeutic potential of diabetic microvascular complications.Frontiers in pharmacology · 2026Review
- From pathogenic carriers to therapeutic hope: the dual role and translational prospects of exosomes in diabetic kidney disease.Frontiers in endocrinology · 2026Review
- Circulating exosomal miR-550a-5p/miR-665 identify coronary microvascular dysfunction and drive endothelial-myocyte crosstalk in type 2 diabetes.Frontiers in cell and developmental biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundDiabetic kidney disease (DKD) is a frequent microvascular complication of diabetes and the predominant cause of end-stage renal disease worldwide. Dysregulated microRNA (miRNA) expression contributes to DKD pathogenesis. This study aimed to determine the clinical significance of serum exosomal miR-1207-5p expression in type-2 DKD.
methodsSerum exosomes were isolated from 51 DKD patients stratified into low-, medium-, high-, and extremely high-risk groups and 11 control individuals. Exsosomal miR-1207-5p expression was determined by real-time-quantitative polymerase chain reaction (RT-qPCR), and its relationship with the patient's clinical records was explored. Bioinformatics analyses were performed to determine miR-1207-5p target genes using tools available online. Datasets obtained from the Gene Expression Omnibus (GEO) database were used to validate the experimental results.
resultsmiR-1207-5p was downregulated in the DKD patients compared to the controls, and this downregulation was the most prominent in the high-risk group. Correlation analysis revealed inverse associations between miR-1207-5p and parameters of renal dysfunction. Multivariate logistic regression indicated that miR-1207-5p may confer protection against DKD progression. Receiver operating characteristic (ROC) curve analysis demonstrated the ability of exosomal miR-1207-5p to distinguish low- versus high-/extremely high-risk DKD. Bioinformatics approaches identified a miR-1207-5p-mediated competing endogenous RNA (ceRNA) network with connections to pathogenic pathways.
conclusionSerum exosomal miR-1207-5p holds promise as a noninvasive biomarker for assessing DKD progression risk and improving the diagnosis and prognosis of affected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.